L&C Bio
- Two KOSDAQ Playbooks: L&C Bio's 140 Billion Won Rights Offer, Bonne's Private Placement
L&C Bio seeks about 140 billion won in a shareholder rights offering while Bonne raises 2.2 billion won from one investor — two KOSDAQ paths to new equity.
- L&C Bio's 140 Billion Won Rights Offering Leads a KOSDAQ Capital-Raising Rush
Three KOSDAQ companies unveiled share sales totaling over 144 billion won, led by L&C Bio's 140 billion won rights offering for facility investment.